

Jean-François Martini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1710559/publications.pdf>

Version: 2024-02-01

13
papers

1,116
citations

1040056

9
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

1578
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1170-1176. | 2.0 | 7 |
| 2 | Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. <i>Future Oncology</i> , 2021, 17, 403-409. | 2.4 | 1 |
| 3 | Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105192. | 1.5 | 22 |
| 4 | Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5598-5608. | 7.0 | 13 |
| 5 | Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868. | 7.0 | 14 |
| 6 | Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. <i>Future Oncology</i> , 2019, 15, 1997-2007. | 2.4 | 6 |
| 7 | Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173. | 7.0 | 23 |
| 8 | Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , 2018, 24, 1554-1561. | 7.0 | 34 |
| 9 | Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415. | 7.0 | 50 |
| 10 | Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 526-533. | 1.9 | 8 |
| 11 | Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , 2016, 375, 2246-2254. | 27.0 | 640 |
| 12 | A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685. | 10.7 | 229 |
| 13 | Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 739-750. | 2.3 | 69 |